12700 related articles for article (PubMed ID: 10711641)
1. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
[TBL] [Abstract][Full Text] [Related]
2. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
Grimm EA; Smid CM; Lee JJ; Tseng CH; Eton O; Buzaid AC
Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
[TBL] [Abstract][Full Text] [Related]
3. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.
Håkansson A; Gustafsson B; Krysander L; Hjelmqvist B; Rettrup B; Håkansson L
Br J Cancer; 2001 Dec; 85(12):1871-7. PubMed ID: 11747328
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
5. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
Keilholz U; Conradt C; Legha SS; Khayat D; Scheibenbogen C; Thatcher N; Goey SH; Gore M; Dorval T; Hancock B; Punt CJ; Dummer R; Avril MF; Bröcker EB; Benhammouda A; Eggermont AM; Pritsch M
J Clin Oncol; 1998 Sep; 16(9):2921-9. PubMed ID: 9738559
[TBL] [Abstract][Full Text] [Related]
6. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.
Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M
Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175
[TBL] [Abstract][Full Text] [Related]
7. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.
Fosså SD; Aamdal S; Naume B; Gallati H
Acta Oncol; 1995; 34(5):599-603. PubMed ID: 7546824
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
[TBL] [Abstract][Full Text] [Related]
11. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
[TBL] [Abstract][Full Text] [Related]
12. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
13. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
14. Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma.
Mouawad R; Ichen M; Rixe O; Benhammouda A; Vuillemin E; Weil M; Khayat D; Soubrane C
Clin Exp Immunol; 1994 Sep; 97(3):342-6. PubMed ID: 8082289
[TBL] [Abstract][Full Text] [Related]
15. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
17. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.
Soubrane C; Mouawad R; Ichen M; Suissa J; Borel C; Vuillemin E; Benhammouda A; Bizzari JP; Weil M; Khayat D
Clin Exp Immunol; 1994 Feb; 95(2):232-6. PubMed ID: 8306497
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
19. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
20. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
